Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXPNASDAQ:KPRXNASDAQ:NCNANASDAQ:PHIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$0.31+0.7%$0.37$0.30▼$3.33$7.21M-1.38176,758 shs194,912 shsKPRXKiora Pharmaceuticals$3.01-0.3%$3.08$2.51▼$5.45$9.16M-0.68133,793 shs27,172 shsNCNANuCana$0.13+14.2%$0.34$0.03▼$10.79$797K1.2434.05 million shs178.89 million shsPHIOPhio Pharmaceuticals$2.48+9.3%$2.09$0.97▼$9.79$10.89M0.842.44 million shs162,714 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals+0.69%-8.30%-20.65%-24.32%-87.36%KPRXKiora Pharmaceuticals-0.33%-7.38%-6.81%-6.52%-43.84%NCNANuCana+14.19%+72.18%+199.54%-84.74%-95.63%PHIOPhio Pharmaceuticals+9.25%-11.11%+34.78%+78.42%-61.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals3.106 of 5 stars3.55.00.00.02.01.70.6KPRXKiora Pharmaceuticals3.3745 of 5 stars3.55.00.00.03.01.70.6NCNANuCana3.6247 of 5 stars3.34.00.00.03.82.51.3PHIOPhio Pharmaceuticals3.9903 of 5 stars3.55.00.00.03.92.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$8.002,505.01% UpsideKPRXKiora Pharmaceuticals 3.00Buy$10.00232.23% UpsideNCNANuCana 2.50Moderate Buy$25.0018,954.88% UpsidePHIOPhio Pharmaceuticals 3.00Buy$14.00464.52% UpsideCurrent Analyst Ratings BreakdownLatest NCNA, KPRX, PHIO, and ACXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.005/15/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$8.004/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/28/2025KPRXKiora PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/19/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.34 per shareN/AKPRXKiora Pharmaceuticals$16M0.57N/AN/A$7.14 per share0.42NCNANuCanaN/AN/AN/AN/A$8.85 per shareN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$18.57 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.58M-$0.70N/AN/AN/AN/A-392.36%-223.78%8/8/2025 (Estimated)KPRXKiora Pharmaceuticals-$12.51M-$2.90N/AN/AN/AN/A21.32%16.39%8/8/2025 (Estimated)NCNANuCana-$34.37M-$7.02N/AN/AN/AN/A-314.47%-112.60%8/13/2025 (Estimated)PHIOPhio Pharmaceuticals-$10.83M-$10.92N/A0.66N/AN/A-134.57%-108.39%8/13/2025 (Estimated)Latest NCNA, KPRX, PHIO, and ACXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2025Q1 2025NCNANuCana-$0.0129-$0.63-$0.6171-$0.63N/AN/A5/12/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14-$0.11+$0.03-$0.11N/AN/A5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77-$0.52+$0.25-$0.52$0.75 millionN/A3/25/2025Q4 2024KPRXKiora Pharmaceuticals-$0.64-$1.04-$0.40-$1.04$0.75 million$0.75 million3/20/2025Q4 2024NCNANuCana-$2.43-$0.32+$2.11-$0.32N/AN/A3/17/2025Q4 2024ACXPAcurx Pharmaceuticals-$0.18-$0.16+$0.02-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A1.801.80KPRXKiora PharmaceuticalsN/A8.978.97NCNANuCanaN/A1.121.12PHIOPhio PharmaceuticalsN/A6.386.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%KPRXKiora Pharmaceuticals76.97%NCNANuCana44.00%PHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals26.00%KPRXKiora Pharmaceuticals0.05%NCNANuCana31.20%PHIOPhio Pharmaceuticals0.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals323.48 million11.99 millionOptionableKPRXKiora Pharmaceuticals103.04 million2.97 millionNot OptionableNCNANuCana306.08 million1.82 millionNot OptionablePHIOPhio Pharmaceuticals104.80 million6.85 millionNot OptionableNCNA, KPRX, PHIO, and ACXP HeadlinesRecent News About These CompaniesFY2025 Earnings Forecast for PHIO Issued By HC WainwrightJune 10, 2025 | americanbankingnews.comQ2 Earnings Estimate for PHIO Issued By HC WainwrightJune 8, 2025 | americanbankingnews.comHC Wainwright Begins Coverage on Phio Pharmaceuticals (NASDAQ:PHIO)June 7, 2025 | americanbankingnews.comPhio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA PortfolioJune 6, 2025 | newsfilecorp.comBest Value Stocks to Buy for May 28thMay 28, 2025 | zacks.comNew Strong Buy Stocks for May 28thMay 28, 2025 | zacks.comPhio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor ConferenceMay 19, 2025 | newsfilecorp.comPhio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | newsfilecorp.comPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical TrialMay 7, 2025 | finanznachrichten.dePhio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical TrialMay 7, 2025 | newsfilecorp.comPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMay 1, 2025 | newsfilecorp.comBest Momentum Stocks to Buy for April 23rdApril 23, 2025 | zacks.comBest Value Stocks to Buy for April 23rdApril 23, 2025 | zacks.comPhio Pharmaceuticals Corp. Common StockApril 12, 2025 | fxempire.comPhio Pharmaceuticals announces Safety Monitoring Committee recommendation to advance INTASYL PH-762 skin cancer studyApril 12, 2025 | pharmabiz.comPhio advances skin cancer treatment with successful trialApril 11, 2025 | uk.investing.comPHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next DoseApril 10, 2025 | zacks.comThis Biotech Is Ripping Following Phase 1b Trial AnnouncementApril 9, 2025 | msn.comPhio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s ThrilledApril 9, 2025 | msn.comPhio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation CohortApril 9, 2025 | newsfilecorp.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNCNA, KPRX, PHIO, and ACXP Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$0.31 +0.00 (+0.69%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$0.31 +0.00 (+0.29%) As of 04:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Kiora Pharmaceuticals NASDAQ:KPRX$3.01 -0.01 (-0.33%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$3.00 0.00 (-0.17%) As of 06/16/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.NuCana NASDAQ:NCNA$0.13 +0.02 (+14.19%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$0.14 +0.00 (+2.90%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Phio Pharmaceuticals NASDAQ:PHIO$2.48 +0.21 (+9.25%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$2.43 -0.05 (-2.02%) As of 06/16/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
